sunitinib malate
sunitinib malate is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand name including Sunitinib Malate. Available dosage forms: powder, capsule.
Drug details
- Generic Name
- sunitinib malate
- Brand Names
- Sunitinib Malate
- Application Number
- ANDA201275
- Sponsor
- Pfizer Asia Manufacturing Pte Ltd
- NDC Codes
- 5
- Dosage Forms
- POWDER, CAPSULE
- Routes
- ORAL
- Active Ingredients
- SUNITINIB MALATE
Indications and Usage
1 INDICATIONS AND USAGE SUTENT is a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) • adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) • treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor SUTENT is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma SUTENT is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.